Literature DB >> 15053237

Ki-ras mutational analysis in rat follicular-cell proliferative lesions of the thyroid gland induced by radioactive iodine and potassium perchlorate.

J M Fernández-Santos1, M De-Miguel, R González-Cámpora, M Salguero-Villadiego, J J Cabrera, H Galera-Davidson.   

Abstract

Although in both human and experimental pathology ras mutations have been related to the origin and progression of follicular-cell tumours, reports differ considerably with respect to the frequency of such mutations. The present paper reports, using direct sequencing, the incidence of Ki-ras mutations (codons 12 and 13) in follicular-cell carcinomas of the thyroid gland in Wistar rats induced by administration of radioactive iodine and potassium perchlorate. Direct sequencing revealed no mutations in the amplified gene segment of any of the 72 carcinoma samples studied. This absence of mutations agrees with some and is in sharp contrast with other previous reports in the literature, both for experimental animals and in studies of human thyroid follicular-cell carcinoma. Our results suggest that Ki-ras activation via mutations at codons 12 and 13 is neither a constant event nor an early event in the development of rat thyroid follicular-cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15053237     DOI: 10.1007/BF03350904

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  27 in total

1.  Agent-specific ras oncogene activation in rat thyroid tumours.

Authors:  N R Lemoine; E S Mayall; E D Williams; V Thurston; D Wynford-Thomas
Journal:  Oncogene       Date:  1988-11       Impact factor: 9.867

2.  Activated ras oncogenes in human thyroid cancers.

Authors:  N R Lemoine; E S Mayall; F S Wyllie; C J Farr; D Hughes; R A Padua; V Thurston; E D Williams; D Wynford-Thomas
Journal:  Cancer Res       Date:  1988-08-15       Impact factor: 12.701

3.  Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype.

Authors:  M Santoro; F Carlomagno; I D Hay; M A Herrmann; M Grieco; R Melillo; M A Pierotti; I Bongarzone; G Della Porta; N Berger
Journal:  J Clin Invest       Date:  1992-05       Impact factor: 14.808

4.  Enhanced expression of EGF receptor and low frequency of ras mutations in X-ray-induced rat thyroid tumours.

Authors:  D R Haugen; J R Lillehaug; L A Akslen
Journal:  Virchows Arch       Date:  1999-10       Impact factor: 4.064

5.  Prevalence of Ras mutations in thyroid neoplasia.

Authors:  C T Esapa; S J Johnson; P Kendall-Taylor; T W Lennard; P E Harris
Journal:  Clin Endocrinol (Oxf)       Date:  1999-04       Impact factor: 3.478

6.  High rates of ras codon 61 mutation in thyroid tumors in an iodide-deficient area.

Authors:  Y F Shi; M J Zou; H Schmidt; F Juhasz; V Stensky; D Robb; N R Farid
Journal:  Cancer Res       Date:  1991-05-15       Impact factor: 12.701

7.  Ras oncogene mutations in thyroid tumors: polymerase chain reaction-restriction-fragment-length polymorphism analysis from paraffin-embedded tissues.

Authors:  G Capella; X Matias-Guiu; X Ampudia; A de Leiva; M Perucho; J Prat
Journal:  Diagn Mol Pathol       Date:  1996-03

8.  Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos.

Authors:  Z Ni; Y Liu; N Keshava; G Zhou; W Whong; T Ong
Journal:  Mutat Res       Date:  2000-06-22       Impact factor: 2.433

Review 9.  Epidemiology of thyroid diseases in iodine sufficiency.

Authors:  P Lind; W Langsteger; M Molnar; H J Gallowitsch; P Mikosch; I Gomez
Journal:  Thyroid       Date:  1998-12       Impact factor: 6.568

10.  High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis.

Authors:  N R Lemoine; E S Mayall; F S Wyllie; E D Williams; M Goyns; B Stringer; D Wynford-Thomas
Journal:  Oncogene       Date:  1989-02       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.